Compare · MGTX vs RVMD
MGTX vs RVMD
Side-by-side comparison of MeiraGTx Holdings plc (MGTX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGTX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $31.57B, about 37.5x MGTX ($841.8M).
- Over the past year, MGTX is up 43.5% and RVMD is up 265.7% - RVMD leads by 222.2 points.
- RVMD has been more active in the news (5 items in the past 4 weeks vs 3 for MGTX).
- RVMD has more recent analyst coverage (25 ratings vs 3 for MGTX).
- Company
- MeiraGTx Holdings plc
- Revolution Medicines Inc.
- Price
- $9.09+0.94%
- $148.49-0.48%
- Market cap
- $841.8M
- $31.57B
- 1M return
- -6.24%
- +4.07%
- 1Y return
- +43.52%
- +265.68%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 3
- 5
- Recent ratings
- 3
- 25
MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest MGTX
- CFO & COO Giroux Richard gifted 7,000 units of Ordinary Shares, decreasing direct ownership by 0.72% to 964,530 units (SEC Form 4)
- PRESIDENT & CEO Forbes Alexandria sold $568,540 worth of Ordinary Shares (62,000 units at $9.17) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,387,695 units (SEC Form 4)
- SEC Form 144 filed by MeiraGTx Holdings plc
- SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Fleck Penny Renee
- SEC Form 3 filed by new insider Fleck Penny Renee
- MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by MeiraGTx Holdings plc
- MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- MeiraGTx Reports First Quarter 2026 Financial and Operational Results
- Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress